Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4779-4779
Open Access | Times Cited: 10

Showing 10 citing articles:

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 21
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4189-4189
Open Access | Times Cited: 13
Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates
Mark E. Petersen, Michael G. Brant, Manuel Lasalle, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 5, pp. 606-618
Open Access | Times Cited: 10
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1410-1410
Open Access | Times Cited: 5
Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies
M. Tabrizi Namini, G. Bhagya, Manjari Sharma
Aspects of Molecular Medicine (2025), pp. 100073-100073
Open Access
Current status of molecular diagnostics for lung cancer
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, С. В. Орлов
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 742-765
Open Access | Times Cited: 2
Non-small cell lung cancer with MET mutation: a clinical case of treatment with MET inhibitor capmatinib
К. V. Menshikov, А. В. Султанбаев, Ш. И. Мусин, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 21, pp. 146-152
Open Access
A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report
Douglas Dias e Silva, Isa Mambetsariev, Jeremy Fricke, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1163-1168
Open Access
Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases
Kaibo Ding, Dujiang Liu, Xuanhong Jin, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113391-113391
Open Access
Page 1

Scroll to top